Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa | Zendy

Hélio S. Sader | Zendy; Robert K. Flamm | Zendy; Glenn E. Dale | Zendy; Paul R. Rhomberg | Zendy; Mariana Castanheira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa

Author(s) -

Hélio S. Sader,

Robert K. Flamm,

Glenn E. Dale,

Paul R. Rhomberg,

Mariana Castanheira

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky227

Subject(s) - colistin , broth microdilution , microbiology and biotechnology , antimicrobial , pseudomonas aeruginosa , tobramycin , cephalosporin , antibiotics , polymyxin , medicine , biology , minimum inhibitory concentration , bacteria , gentamicin , genetics

Murepavadin (POL7080) represents the first member of a novel class of outer membrane protein-targeting antibiotics. Murepavadin acts by binding to LPS transport protein D and is being developed for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research